Sabri Barutca
Overview
Explore the profile of Sabri Barutca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanriverdi O, Ozdemir M, Hafizoglu E, Guclu T, Almurodova E, Kitapli S, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2025 Feb;
:1-11.
PMID: 39899025
Background: This study explores Turkish medical oncologists' perceptions of integrating international treatment guidelines with national reimbursement policies, considering local legal, economic, and healthcare constraints. Research Design And Methods: A cross-sectional...
2.
Demir B, Demirci B, Tataroglu C, Barutca S, Barutca D
Cutan Ocul Toxicol
. 2024 Jan;
43(2):113-119.
PMID: 38179974
Objective: Chemotherapy induced alopecia (CIA) is one of the most common side effects in cancer patients, however; it doesn't have an effective pharmacological treatment yet. In this study we aimed...
3.
Uygur E, Sezgin C, Parlak Y, Karatay K, Arikbasi B, Avcibasi U, et al.
Res Sq
. 2023 Nov;
PMID: 37961521
Background: Prostate cancer (PC) is the most common type of cancer in elderly men, with a positive correlation with age. As resistance to treatment has developed, particularly in the progressive...
4.
Ekinci F, Erdogan A, Yildirim S, Bulut G, Yilmaz C, Barutca S
J Coll Physicians Surg Pak
. 2022 Oct;
32(10):1288-1294.
PMID: 36205273
Objective: To evaluate the utility of inflammatory prognostic index (IPI), albumin, c-reactive protein (CRP), and lactate dehydrogenase (LDH) as predictive biomarkers of oncologic outcome in metastatic renal cell cancer (mRCC)...
5.
Yilmaz H, Nigdelioglu B, Aytac A, Turan M, Oktay E, Yersal O, et al.
Future Oncol
. 2022 Sep;
18(27):3043-3053.
PMID: 36062468
To demonstrate the prognostic importance of glucose-to-lymphocyte ratio (GLR) and uric acid (UA) in patients with metastatic breast cancer (MBC) receiving Cdk 4/6 inhibitors. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, GLR, UA...
6.
Erdogan A, Ekinci F, Karabas A, Balcik O, Barutca S, Dirican A
J Gastrointest Cancer
. 2021 Apr;
53(1):45-51.
PMID: 33881720
Purpose: To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib. Methods: A retrospective analysis of 65 metastatic CRC patients...
7.
Kalemci S, Tanriverdi O, Simsek A, Aksun S, Celik O, Barutca S, et al.
Contemp Oncol (Pozn)
. 2019 Dec;
23(3):151-156.
PMID: 31798330
Introduction: The mechanism of oxaliplatin (OXA) induced pulmonary toxicity is not fully understood. Aim Of The Study: The present study was designed to investigate the pulmonary toxicity of OXA that...
8.
Yersal O, Kaplan M, Isikdogan A, Ozdemir N, Aliustaoglu M, Barutca S, et al.
Mol Clin Oncol
. 2019 Jan;
10(1):180-184.
PMID: 30655995
Nodal (N) status and molecular subtypes are well-known prognostic factors for breast cancer patients. The aim of the present study was to evaluate whether there was a prognostic role of...
9.
Oktay E, Levent M, Gelincik H, Aktas G, Yumuk F, Koral L, et al.
J Cancer Educ
. 2018 Nov;
35(1):69-75.
PMID: 30446981
Cancer is one of the most common causes of death all over the World (Rahib et al. in Cancer Res 74(11):2913-2921, 2014; Silbermann et al. in Ann Oncol 23(Suppl 3):iii15-iii28,...
10.
Yersal O, Eryilmaz U, Akdam H, Meydan N, Barutca S
Cardiol Res Pract
. 2018 Jun;
2018:5352914.
PMID: 29854434
Aims: Cardiovascular diseases are the primary cause of premature morbidity and mortality in early breast cancer patients after treatment with cardiotoxic chemotherapeutic agents. Arterial stiffness is an independent risk factor...